首页> 美国卫生研究院文献>other >Quantified Pathologic Response Assessed as Residual Tumor Burden is a Predictor of Recurrence-free Survival in Patients with Rectal Cancer Resected after Neoadjuvant Chemoradiotherapy

【2h】

Quantified Pathologic Response Assessed as Residual Tumor Burden is a Predictor of Recurrence-free Survival in Patients with Rectal Cancer Resected after Neoadjuvant Chemoradiotherapy

机译：评估为残余肿瘤负担的量化病理反应是新辅助放化疗后切除的直肠癌患者无复发生存的预测指标

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectiveTo determine whether quantified pathologic response assessed as a percentage of residual tumor cells predicts recurrence-free survival (RFS) in patients with rectal cancer.

机译：目的确定以残余肿瘤细胞百分比评估的量化病理反应是否可预测直肠癌患者的无复发生存期（RFS）。

著录项

期刊名称 other
作者
A. Agarwal; G. J. Chang; C. Hu; M. Taggart; A. Rashid; I. J. Park; Y. N. You; P. Das; S. Krishnan; C. H. Crane; M. Rodriguez-Bigas; J. Skibber; L. Ellis; C. Eng; S. Kopetz; D. M. Maru;
展开▼
作者单位

展开▼
年(卷),期 -1(119),24
年度 -1
页码 4231–4241
总页数 20
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy [J] . AgarwalA., ChangG.J., HuC.-Y., Cancer: A Journal of the American Cancer Society . 2013,第24期

机译：被评估为残留的肿瘤负担的量化病理反应是在Neoadjuvant ChemorAdiotapy疗法中进行切除切除的直肠癌患者的复发存活的预测
2. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy [J] . AgarwalA., ChangG.J., HuC.-Y., Cancer: A Journal of the American Cancer Society . 2013,第24期

机译：被评估为残留的肿瘤负担的量化病理反应是在Neoadjuvant ChemorAdiotapy疗法中进行切除切除的直肠癌患者的复发存活的预测
3. Reply to Can quantified pathologic response assessed as residual tumor burden be a promising staging system for patients with rectal cancer treated with chemoradiation followed by surgery? [J] . Dipen M Maru, Atin A Agarwal, Chung-Yuan Hu, Cancer: A Journal of the American Cancer Society . 2014,第8期

机译：对于以化学放射治疗并随后接受手术治疗的直肠癌患者，可以将量化的病理反应评估为残余肿瘤负荷量是否可以成为一种有前途的分期系统？
4. Texture kinetic features from pre-treatment DCE MRI for predicting pathologic tumor stage regression after neoadjuvant chemoradiation in rectal cancers [C] . Siddhartha Nanda, Jacob T. Antunes, Kaustav Bera, Conference on Medical Imaging: Image-Guided Procedures, Robotic Interventions, and Modeling . 2020

机译：预处理DCE MRI的纹理动力学特征可预测直肠癌新辅助化学放疗后病理性肿瘤分期
5. Using Preoperative Mri-guided Biopsies to Predict Pathologic Complete Response after Neoadjuvant Chemotherapy in Breast Cancer [D] . Kim, Jiyoon. 2019

机译：在乳腺癌新辅助化疗后使用术前Mri引导的活检来预测病理完全缓解
6. Nomogram Predicting Overall Survival of Resected Locally Advanced Rectal Cancer Patients with Neoadjuvant Chemoradiotherapy [O] . Jianyuan Song, Zhuhong Chen, Daxin Huang, 2020

机译：NOMAPROM预测Encoadjuvant ChemoRAdiOurapy切除局部晚期直肠癌患者的整体存活
7. Nomogram to Predict Distant Metastasis Probability for Pathological Complete Response Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy [O] . Ting Jiang, Shuang Liu, Xiaojun Wu, 2021

机译：NOMAGOM以预测新辅助化学疗法后病理完全反应直肠癌患者的远程转移概率

Quantified Pathologic Response Assessed as Residual Tumor Burden is a Predictor of Recurrence-free Survival in Patients with Rectal Cancer Resected after Neoadjuvant Chemoradiotherapy

摘要

著录项

相似文献

相关主题

期刊订阅